AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03530228
Drug: Tegoprazan (C2)
RxNorm normalized name: Tegoprazan
DrugBank: Tegoprazan (DB16690)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tegoprazan QD, oral administration, for 7 days. Group 1
Trial: NCT03530228
Drug: Tegoprazan (C2)
RxNorm normalized name: Tegoprazan
DrugBank: Tegoprazan (DB16690)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tegoprazan QD, oral administration, for 7 days. Group 2
Trial: NCT03530228
Drug: Esomeprazole (C2)
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Esomeprazole QD, oral administration, for 7 days. Group 3
Trial: NCT03530228
Drug: Tegoprazan (C3)
RxNorm normalized name: Tegoprazan
DrugBank: Tegoprazan (DB16690)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tegoprazan QD, oral administration
Trial: NCT00001270
Drug: interleukin-1
RxNorm normalized name: Interleukin-1
DrugBank: Interleukin-10 (DB12880)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03546959
Drug: Botulinum Toxin
RxNorm normalized name: Botulinum toxin
DrugBank: Botulinum toxin type B (DB00042)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin injection for upper limb spasticity after stroke
Trial: NCT00934882
Drug: Regorafenib (BAY73-4506)
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administration of the multi-kinase inhibitor BAY73-4506 (160 mg once daily from Day 4 to Day 10 and from Day 18 to Day 24) as oral treatment in combination with the chemotherapy regimen mFOLFOX6 or FOLFIRI in patients with metastatic Colorectal Cancer
Trial: NCT02000947
Drug: Tremelimumab
RxNorm normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tremelimumab is an anti-CTLA4 monoclonal antibody (mAb).
Trial: NCT02000947
Drug: tremelimumab
RxNorm normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tremelimumab is an anti-CTLA4 monoclonal antibody (mAb).
Trial: NCT03071744
Drug: Lazanda
RxNorm normalized name: Lazanda
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lazanda is supplied in glass bottles, containing 8 sprays of 100 mcL containing 100 mcg/100 mcL or 400 mcg/100 mcL concentration solution.
Trial: NCT00095771
Drug: arsenic trioxide
RxNorm normalized name: Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02557789
Drug: Lefamulin
RxNorm normalized name: LEFAMULIN
DrugBank: Lefamulin (DB12825)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lefamulin administered iv or orally in the fasted state and orally in the fed state
Trial: NCT01121926
Drug: Trazodone HCl
RxNorm normalized name: trazodone HCl
DrugBank: Trazodone (DB00656)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dosage form:~Extended-release caplets containing 300 mg trazodone HCl and extended-release caplets containing 150 mg trazodone HCl (the 150 mg dosage form was only used for the up and down titration, and was not evaluated in the study).~Dose regimen:~75 mg trazodone HCl (½ x 150 mg extended-release caplet) on Days 1 and 11, 150 mg trazodone HCl (one extended-release caplet) on Days 2 and 10, 300 mg trazodone HCl (one extended-release caplet) on Days 3 to 9, each at 23:30 after a fast of at least 4 hours.
Trial: NCT01121926
Drug: Trazodone HCl
RxNorm normalized name: trazodone HCl
DrugBank: Trazodone (DB00656)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dosage form:~Immediate-release tablet containing 100 mg trazodone HCl~Dose regimen:~100 mg trazodone HCl (one immediate-release tablet) once (at 23:30) on Days 1 and 11, 100 mg trazodone HCl (one immediate-release tablet) twice (at 23:30 and 11:30) on Days 2 and 10, 100 mg trazodone HCl (one immediate-release tablet) three times daily (at 23:30, 07:30 and 15:30) on Days 3 to 9. Evening doses were administered after a fast of at least 4 hours.
Trial: NCT00530075
Drug: Gusperimus
RxNorm normalized name: gusperimus
DrugBank: Gusperimus (DB12692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC, 0.5mg/kg/day, consecutive 21 days administration, 1 to 2 weeks rest, 6 cycles
Trial: NCT03928327
Drug: TAK-788
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-788 Capsules
Trial: NCT03928327
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Itraconazole Oral solution
Trial: NCT03928327
Drug: Rifampin
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin Capsules
Trial: NCT00474032
Drug: Botulinum Toxin (Type A) injection (10 U/Kg)
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type B (DB00042)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: See Detailed Description.
Trial: NCT00174395
Drug: eletriptan
RxNorm normalized name: Eletriptan
DrugBank: Eletriptan (DB00216)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01726686
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 ml Ropivacaine 10mg/ml in a continuous infusion pump set at 2 ml/hour
Trial: NCT01363271
Drug: Linezolid
RxNorm normalized name: Linezolid
DrugBank: Linezolid (DB00601)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV and oral forms of linezolid are identified through a pre-specified list of National Drug Codes (NDCs).
Trial: NCT01363271
Drug: Vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV form of vancomycin is identified through a pre-specified list of National Drug Codes (NDCs).
Trial: NCT02004171
Drug: nicotine inhaler
RxNorm normalized name: nicotine Inhalation Solution
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: nicotine inhaler with 10 mg nicotine cartridges
Trial: NCT00143351
Drug: Ziprasidone
RxNorm normalized name: Ziprasidone
DrugBank: Ziprasidone (DB00246)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01111149
Drug: Varenicline
RxNorm normalized name: Varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects in the varenicline group will receive one 1mg pill/day for week 0, followed by two 1mg pills/day for the rest of the study.
Trial: NCT01111149
Drug: Bupropion HCl
RxNorm normalized name: bupropion HCl
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: in the Bupropion HCl group will receive one 150mg pill/day for week 0, followed by two 150mg pills/day for the rest of the study
Trial: NCT00189514
Drug: pramlintide acetate
RxNorm normalized name: Pramlintide Acetate
DrugBank: Pramlintide (DB01278)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection, twice a day or three times a day, at doses of 120mcg, 240mcg, or 360mcg
Trial: NCT03535870
Drug: Fluticasone propionate/salmeterol
RxNorm normalized name: fluticasone propionate/salmeterol 100/50 MCG/INHAL Dry Powder Inhaler, 14 Blisters
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered via the LOMI inhaler device
Trial: NCT00061880
Drug: forodesine hydrochloride
RxNorm normalized name: Forodesine hydrochloride
DrugBank: Forodesine (DB06185)
FDA approved: no
EMA approved: no
PMDA approved: yes
Trial: NCT00357162
Drug: belinostat
RxNorm normalized name: Belinostat
DrugBank: Belinostat (DB05015)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01594268
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: A prospective, open-label study to assess safety of Certican in kidney transplant patients
Trial: NCT04613869
Drug: High-dose Esketamine hydrochloride+Hydromorphone
RxNorm normalized name: esketamine hydrochloride
DrugBank: Hydromorphone (DB00327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: By adding different doses of esketamine to the postoperative analgesic pump, and the control group without adding this drug to observe the postoperative pain, anxiety and depression indicators of the surgical patients
Trial: NCT04613869
Drug: Low-dose Esketamine hydrochloride+Hydromorphone
RxNorm normalized name: ethinyl estradiol
DrugBank: Hydromorphone (DB00327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: By adding different doses of esketamine to the postoperative analgesic pump, and the control group without adding this drug to observe the postoperative pain, anxiety and depression indicators of the surgical patients
Trial: NCT04613869
Drug: Hydromorphone
RxNorm normalized name: Hydromorphone
DrugBank: Hydromorphone (DB00327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No esketamine added
Trial: NCT03055195
Drug: Mepolizumab 100 mg
RxNorm normalized name: mepolizumab 100 MG
DrugBank: Mepolizumab (DB06612)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Mepolizumab is available as lyophilized powder in sterile vials for injection. The content is reconstituted with 1.2 milliliter (mL) Sterile Water just prior to use. Subjects will receive 1mL (100 mg/mL) bolus subcutaneous injections.
Trial: NCT03055195
Drug: Placebo matching mepolizumab
DrugBank: Mepolizumab (DB06612)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Placebo is available as 0.9% sodium chloride solution. Subjects will receive 1mL bolus subcutaneous injections.
Trial: NCT01908842
Drug: BNX sublingual tablets
RxNorm normalized name: BNX
DrugBank: Oxybuprocaine (DB00892)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Buprenorphine/naloxone sublingual tablets
Trial: NCT01908842
Drug: BNX sublingual film
RxNorm normalized name: BNX
DrugBank: Oxybuprocaine (DB00892)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Buprenorphine/naloxone sublingual film
Trial: NCT01908842
Drug: Buprenorphine
RxNorm normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Buprenorphine sublingual tablets
Trial: NCT00113685
Drug: Hypertonic Saline-Dextran Solution
RxNorm normalized name: dextran 70 Injectable Solution
DrugBank: Dextran (DB09255)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00113685
Drug: Lactated Ringer's Solution
RxNorm normalized name: Lactated Ringer's Solution Intravenous Solution
DrugBank: Potassium chloride (DB00761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01053936
Drug: Bardoxolone methyl (amorphous dispersion)
RxNorm normalized name: methylal
DrugBank: Bardoxolone methyl (DB05983)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, once daily
Trial: NCT00396669
Drug: Bupropion
RxNorm normalized name: Bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: We measure dopamine release at the striatum using 11 C Raclopride at baseline and after smoking a cigarette
Trial: NCT00396669
Drug: Bupropion
RxNorm normalized name: Bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brain imaging after treatment with Bupropion
Trial: NCT01027416
Drug: Tamoxifen
RxNorm normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug: Tamoxifen 20 mg orally 1x/day for 4 weeks
Trial: NCT01566162
Drug: Lurasidone
RxNorm normalized name: Lurasidone
DrugBank: Lurasidone (DB08815)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lurasidone 40-80 mg taken orally taken once daily
Trial: NCT00081458
Drug: Teduglutide 0.05 mg/kg/d
DrugBank: Teduglutide (DB08900)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Teduglutide 0.05 mg/kg/d daily injectable subcutaneously into the thigh or abdomen
Trial: NCT00081458
Drug: Teduglutide 0.1 mg/kg/d
DrugBank: Teduglutide (DB08900)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Teduglutide 0.1 /g/kg/d daily injection subcutaneously into thigh or abdomen
Trial: NCT04368910
Drug: Pyronaridine - artesunate
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral pyronaridine artesunate (180:60 mg tablets), plus chloroquine-placebo once a day for 3 consecutive days.
Trial: NCT04368910
Drug: Chloroquine
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral chloroquine (155 mg tablets), plus pyronaridine artesunate-placebo, once a day for 3 consecutive days.
Trial: NCT00549328
Drug: Pazopanib (GW786034)
DrugBank: Pazopanib (DB06589)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pazopanib monotherapy
Trial: NCT04505917
Drug: dinoprostol
RxNorm normalized name: Dinoprostone
DrugBank: Dinoprost (DB12789)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the study nurse 3 hours before IUD insertion.
Trial: NCT04505917
Drug: misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 vaginal tablet of misoprostol (200 mcg) (Misotac®; Sigma Pharma, SAE, Egypt) inserted by the study nurse 3 hours before IUD insertion.
Trial: NCT03818932
Drug: Hydrocodone-Acetaminophen
RxNorm normalized name: Dolorex Forte (hydrocodone / acetaminophen) Oral Capsule
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditionally used narcotic pain protocol
Trial: NCT03818932
Drug: Gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Post-Operative Non Opioid Pain Protocol
Trial: NCT03818932
Drug: Diazepam
RxNorm normalized name: Diazepam
DrugBank: Diazepam (DB00829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Post-Operative Non Opioid Pain Protocol
Trial: NCT00523380
Drug: recombinant interleukin-21
RxNorm normalized name: Recombinant interleukin-11
DrugBank: Oprelvekin (DB00038)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered i.v. in treatment cycles of 28 days.
Trial: NCT00523380
Drug: caelyx (pegylated liposomal doxorubicin)
RxNorm normalized name: Caelyx
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered i.v. in treatment cycles of 28 days.
Trial: NCT01243424
Drug: linagliptin
RxNorm normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: linagliptin tablets 5mg QD
Trial: NCT01243424
Drug: glimepiride
RxNorm normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: glimepiride over-encapsulated tablet 1-4 mg QD
Trial: NCT01243424
Drug: linagliptin placebo
DrugBank: Linagliptin (DB08882)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: linagliptin placebo
Trial: NCT01243424
Drug: glimepiride placebo
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: glimepiride placebo
Trial: NCT01197235
Drug: darbepoetin-α
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infusion of darbepoetin-α 1.5 μg/kg will be performed 1 hour before angiography
Trial: NCT03843970
Drug: Levobupivacaine Hydrochloride 0.5%
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The solution is called L solution, which contains a combination of 0.5% isobaric levobupivacaine with fentanyl. Injectable Solution.
Trial: NCT03843970
Drug: Isobaric bupivacaine 0.5%
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The solution is called B solution, which contains a combination of 0.5% isobaric bupivacaine with fentanyl. Injectable Solution.
Trial: NCT02528136
Drug: Carbetocin
RxNorm normalized name: Carbetocin
DrugBank: Carbetocin (DB01282)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02528136
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02475057
Drug: Degarelix (LHRH antagonist)
RxNorm normalized name: Degarelix
DrugBank: Degarelix (DB06699)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Two initial loading doses of 120mg Degarelix for 1 month followed by 80mg monthly for eleven additional months.
Trial: NCT02080078
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00696566
Drug: Clopidogrel and Rifampicin
RxNorm normalized name: rifampicin and isoniazid
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Clopidogrel: loading dose of 600 mg, then 75 mg o.d. for up to 28 days~Rifampicin: 300 mg b.d. for up to 28 days
Trial: NCT03752931
Drug: Celiprolol
RxNorm normalized name: celiprolol
DrugBank: Celiprolol (DB04846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: receiving 1 tablet per day of Celiprolol 200 mg in the morning from the first postoperative day after pneumonectomy or bi lobecomty for 2 weeks.
Trial: NCT03752931
Drug: Diltiazem
RxNorm normalized name: Diltiazem
DrugBank: Diltiazem (DB00343)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: receiving 1 tablet per day of Diltiazem 200 mg in the morning from the first postoperative day after pneumonectomy or bi lobecomty for 2 weeks.
Trial: NCT00422175
Drug: BAF 312
RxNorm normalized name: Bafiertam
DrugBank: Monomethyl fumarate (DB14219)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01857271
Drug: Erlotinib Hydrochloride
RxNorm normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT02489201
Drug: donafenib tosilate tablets
RxNorm normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200mg,bid
Trial: NCT01138046
Drug: Lapatinib in combination with weekly paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: These subjects will receive weekly paclitaxel (80 mg/m2 IV for 3 weeks in a 4 week cycle) plus lapatinib (1500 mg once daily, starting on the second day of phase I). Subjects will receive a daily dose of lapatinib until disease progression or withdrawal from study treatment due to unacceptable toxicity or withdrawal of consent. Study completion is defined as deaths after administering study treatment for more than once. Subjects will be treated with paclitaxel for standard of 6 cycles, and may be continued at the discretion of investigators. If the subject experiences progression, an unacceptable toxicity related to paclitaxel, or termination of lapatinib therapy, paclitaxel therapy must be terminated any time of study period, even before 6 cycles of paclitaxel are given.
Trial: NCT00827242
Drug: tadalafil
RxNorm normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Following a 4-week placebo lead-in period, subjects received tadalafil 5 mg tablet by mouth once daily over a 12-week period.
Trial: NCT02473601
Drug: Mivacurium Chloride
RxNorm normalized name: Mivacurium Chloride
DrugBank: Mivacurium (DB01226)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anesthesia induction:~Intravenous injection of midazolam 0.05 mg/kg,Etomidate 0.3 mg/kg,Sufentanil 0.5 g/kg,TOF detection and adjustment of the first twitch height (T1)100%, Mivacurium Chloramine 0.07 mg/kg intraveous injecting in 5 minutes.~Anesthesia maintenance:~Two groups of sevoflurance 1%\~8% inhalation anesthesia plus intravenous infusion of remifentanil 0.05～0.2 µg/kg/min,Mivacurium Chloramine 6mg/kg/h, Appropriate supplementary analgesia dose of sufentanil before skin incision and the abdomen was closed. The two groups were maintained until the Bis value was 40 \~ 60. PetCO2 was 30 \~ 35mmHg. Hemodynamic fluctuations did not exceed 20% of the baseline value.At least 20 minutes before the operation stopping Mivacurium infusion,Before the end of operation 5-10 minutes stopping infusion of remifentanil and sevoflurane.
Trial: NCT02842099
Drug: X
RxNorm normalized name: AX
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capecitabine
Trial: NCT02919605
Drug: Single dose of Pentamidine
DrugBank: Pentamidine (DB00738)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patients will come to the hospital to take a single dose of the Pentamidine.
Trial: NCT02919605
Drug: Two doses of Pentamidine
DrugBank: Pentamidine (DB00738)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patients will come to the hospital to take two doses of the Pentamidine, in interval of one week between them.
Trial: NCT02919605
Drug: Three doses of Pentamidine
DrugBank: Pentamidine (DB00738)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patients will come to the hospital to take three doses of the Pentamidine, in interval of one week between them.
Trial: NCT05807503
Drug: Cerebrolysin
RxNorm normalized name: cerebrolysin
DrugBank: Cerebrolysin (DB16599)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerebrolysin administration in short period of time after TBI
Trial: NCT01119222
Drug: Gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsule, single 1200mg dose
Trial: NCT01119222
Drug: Diphenhydramine
RxNorm normalized name: Diphenhydramine
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet, single 50mg dose
Trial: NCT01119222
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV, single 10mg dose
Trial: NCT04806425
Drug: Intralipid
RxNorm normalized name: Intralipid
DrugBank: Soybean oil (DB09422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intralipid is given as a preconditioning drug during off bump coronary artery bypass grafting surgery to measure efficacy in decreasing post operative ischemia
Trial: NCT04452006
Drug: ACT-541478 10 mg
RxNorm normalized name: ACT-541468
DrugBank: Daridorexant (DB15031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ACT-541478 will be provided in HPMC capsules for oral administration at a dose strength of 10 mg.
Trial: NCT04452006
Drug: ACT-541478 30 mg
RxNorm normalized name: ACT-541468
DrugBank: Daridorexant (DB15031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ACT-541478 will be provided in HPMC capsules for oral administration at a dose strength of 10 mg.
Trial: NCT04452006
Drug: ACT-541478 100 mg
RxNorm normalized name: ACT-541468
DrugBank: Daridorexant (DB15031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ACT-541478 will be provided in HPMC capsules for oral administration at a dose strength of 50 mg.